Search

Your search keyword '"Brethon, Benoit"' showing total 233 results
Start Over Author "Brethon, Benoit"
233 results on '"Brethon, Benoit"'

4. Varicella post-exposure management for pediatric oncology patients

Author

Costa, Guillaume, Orbach, Daniel, Saulpic, Juliette, Sarda-Thibault, Hélène, Hanslik, Thomas, Brethon, Benoit, Tabone, Marie-Dominique, Raimbault, Sandra, Papillard, Solesne, Guillaumat, Cécile, Nathanson, Sylvie, Pellegrino, Béatrice, Belloy, Marie, Mesples, Bettina, Trioche, Pascale, Jaber, Hania, Raimondo, Graziella, Gilet, Céline, and Cohen-Gogo, Sarah

Published
2022
Full Text
View/download PDF

6. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Author

Ribelles, A Juan, Balduzzi, Adriana, Elhaddad, Alaa, Casanovas, Alejandra, Garcia Velazquez, Alejandra, Laptsevich, Aliaksandra, Chang, Alicia, F. Sampaio, Alessandra Lamenha, González Prieto, Almudena, Lassaletta, Alvaro, Suarez M, Amaranto, Alcasabas, Ana Patricia, Colita, Anca, Morales La Madrid, Andres, Samudio, Angélica, Tondo, Annalisa, Colombini, Antonella, Kattamis, Antonis, Lopez Facundo, N Araceli, Bhattacharyya, Arpita, Alimi, Aurélia, Phulpin, Aurélie, Vakrmanova, Barbora, Aksoy, Basak A, Brethon, Benoit, Kobuin, Jator Brian, Nolasco Monteiro, Carla, Paillard, Catherine, Vezina, Catherine, Ceyhun, Bozkurt, Hentea, Cristiana, Meazza, Cristina, Ortiz-Morales, Daniel, Solorzano, Roque Daniel, Arce Cabrera, Daniela, Zama, Daniele, Ghosh, Debjani, Ramírez-Rivera, Diana, Calle Jara, Doris A, Janic, Dragana, Rey Helo, Elianneth, Gouache, Elodie, Guerrero Quiroz, Enmanuel, Lopez, Enrique, Thebault, Eric, Maradiegue, Essy, de Berranger, Eva, Ebeid, Fatma S E, Galaverna, Federica, Antillon-Klussmann, Federico, Espinoza Chacur, Felipe, Negro, Fernando Daniel, Carraro, Francesca, Compagno, Francesca, Barriga, Francisco, Tamayo Pedraza, Gabriela, Sanchez Fernandez, Gissela, Naidu, Gita, Tokuc, Gülnur, Alias, Hamidah, B Segocio, Hannah Grace, Boudiaf, Houda, Asetre Luna, Imelda, Maia, Iris, Astigarraga, Itziar, Maza, Ivan, Montoya Vásquez, Jacqueline E, Jazbec, Janez, Lazic, Jelena, Beck Dean, Jeniffer, Rouger-Gaudichon, Jeremie, Contreras González, Johanny Carolina, Huerta Aragonés, Jorge, Fuster, José L, Quintana, Juan, Palma, Julia, Svojgr, Karel, Quintero, Karina, Malic Tudor, Karolina, Georgantzi, Kleopatra, P Schultz, Kris Ann, Ureña Horno, Laura, Fraquelli, Lidia, Meneghello, Linda, Shalaby, Lobna, Macias Mora, Lola L, A Renner, Lorna, Nunes Silva, Luciana, Sisinni, Luisa, Hammad, Mahmoud, Fernández Sanmartín, M, Zubieta A, C Marcela, Drozdowski, María Constanza, Kourti, Maria, Palladino, Marcela María, Miranda Madrazo, Maria R, Poiree, Marilyne, Popova, Marina, Melgar, Mario, Baragaño, Marta, Avilés-Robles, Martha J, Provenzi, Massimo, Mendes Lins, Mecneide, Fatih Orhan, Mehmet, Villarroel, Milena, Jerónimo, Mónica, Varas Palma, Mónica, Rafie Raza, Muhammad, M Justin, Mulindwa, Shaheen, Najma, Domínguez-Pinilla, Nerea, Whipple, Nicholas S, André, Nicolas, Hrusak, Ondrej, Velasco Puyó, Pablo, Zacasa Vargas, Pamela, Olate Mellado, Paola, Yola Gassant, Pascale, Diaz Romero, Paulina, De Santis, Raffaella, Kebudi, Rejin, Boranbayeva, Riza, Vasquez, Roberto, Segura, Romel A., Rosado, Roy Enrique, Gómez, Sandra, Raimbault, Sandra, Gunasekera, Sanjeeva, Makkeyah, Sara M, Buyukkapu Bay, Sema, M Gómez, Sergio, Bouttefroy, Séverine, Islam, Shahnoor, Abouelnaga, Sherif, Torres, Silvio Fabio, Cesaro, Simone, Nunes, Sofia, Rouxinol, Soraia, Bhaumik, Sucharita, Saliyeva, Symbat, Inostroza, Tamara, Velasquez, Thelma, Hnin, Tint Myo, Norén-Nyström, Ulrika, Baretta, Valentina, Jimenez-Antolinez, Yajaira Valentine, Pérez Alonso, Vanesa, Ayer Miller, Vanessa, Gandemer, Virginie, Lotero, Viviana, Mishkova, Volha, Gómez-García, Wendy, Margaryan, Yeva, Syed, Yumna, Mukkada, Sheena, Bhakta, Nickhill, Chantada, Guillermo L, Chen, Yichen, Vedaraju, Yuvanesh, Faughnan, Lane, Homsi, Maysam R, Muniz-Talavera, Hilmarie, Ranadive, Radhikesh, Metzger, Monika, Friedrich, Paola, Agulnik, Asya, Jeha, Sima, Lam, Catherine, Dalvi, Rashmi, Hessissen, Laila, Moreira, Daniel C, Santana, Victor M, Sullivan, Michael, Bouffet, Eric, Caniza, Miguela A, Devidas, Meenakshi, Pritchard-Jones, Kathy, and Rodriguez-Galindo, Carlos

Published
2021
Full Text
View/download PDF

7. Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study

Author

Olivier-Gougenheim, Laura, Rama, Nicolas, Dupont, Damien, Saultier, Paul, Leverger, Guy, AbouChahla, Wadih, Paillard, Catherine, Gandemer, Virginie, Theron, Alexandre, Freycon, Claire, Pluchart, Claire, Blouin, Pascale, Pellier, Isabelle, Thouvenin-Doulet, Sandrine, Desplantes, Claire, Ducassou, Stephane, Oudot, Caroline, Rouger-Gaudichon, Jeremie, Cheikh, Nathalie, Poiree, Maryline, Schneider, Pascale, Plat, Genevieve, Contet, Audrey, Rialland, Fanny, Gouache, Elodie, Brethon, Benoit, Bertrand, Yves, and Domenech, Carine

Published
2021
Full Text
View/download PDF

8. COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)

Author

Rouger-Gaudichon, Jérémie, Bertrand, Yves, Boissel, Nicolas, Brethon, Benoit, Ducassou, Stéphane, Gandemer, Virginie, Halfon-Domenech, Carine, Leblanc, Thierry, Leverger, Guy, Michel, Gérard, Petit, Arnaud, Ray-Lunven, Anne-France, Rohrlich, Pierre-Simon, Schneider, Pascale, Sirvent, Nicolas, Strullu, Marion, and Baruchel, André

Published
2021
Full Text
View/download PDF

9. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Author

Brivio, Erica, Locatelli, Franco, Lopez-Yurda, Marta, Malone, Andrea, Díaz-de-Heredia, Cristina, Bielorai, Bella, Rossig, Claudia, van der Velden, Vincent H.J., Ammerlaan, Anneke C.J., Thano, Adriana, van der Sluis, Inge M., den Boer, Monique L., Chen, Ying, Sleight, Barbara, Brethon, Benoit, Nysom, Karsten, Sramkova, Lucie, Øra, Ingrid, Vinti, Luciana, Chen-Santel, Christiane, and Zwaan, Christian Michel

Published
2021
Full Text
View/download PDF

10. COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)

Author

Baruchel, André, Bertrand, Yves, Boissel, Nicolas, Brethon, Benoit, Ducassou, Stéphane, Gandemer, Virginie, Halfon-Domenech, Carine, Leblanc, Thierry, Leverger, Guy, Michel, Gérard, Petit, Arnaud, Ray-Lunven, Anne-France, Rohrlich, Pierre-Simon, Schneider, Pascale, Sirvent, Nicolas, and Strullu, Marion

Published
2020
Full Text
View/download PDF

11. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Author

Pennesi, Edoardo, primary, Brivio, Erica, additional, Ammerlaan, Anneke C. J., additional, Jiang, Yilin, additional, Van der Velden, Vincent H. J., additional, Beverloo, H. Berna, additional, Sleight, Barbara, additional, Locatelli, Franco, additional, Brethon, Benoit, additional, Rossig, Claudia, additional, Engstler, Gernot, additional, Nilsson, Anna, additional, Bruno, Benedicte, additional, Petit, Arnaud, additional, Bielorai, Bella, additional, Rizzari, Carmelo, additional, Rialland, Fanny, additional, Rubio-San-Simón, Alba, additional, Sirvent, Francisco J. Bautista, additional, Diaz-de-Heredia, Cristina, additional, Rives, Susana, additional, and Zwaan, Christian M., additional

Published
2024
Full Text
View/download PDF

14. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Author

Petit, Arnaud, Trinquand, Amélie, Chevret, Sylvie, Ballerini, Paola, Cayuela, Jean-Michel, Grardel, Nathalie, Touzart, Aurore, Brethon, Benoit, Lapillonne, Hélène, Schmitt, Claudine, Thouvenin, Sandrine, Michel, Gerard, Preudhomme, Claude, Soulier, Jean, Landman-Parker, Judith, Leverger, Guy, Macintyre, Elizabeth, Baruchel, André, and Asnafi, Vahid

Published
2018
Full Text
View/download PDF

16. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

Author

van der Sluis, Inge M., primary, de Lorenzo, Paola, additional, Kotecha, Rishi S., additional, Attarbaschi, Andishe, additional, Escherich, Gabriele, additional, Nysom, Karsten, additional, Stary, Jan, additional, Ferster, Alina, additional, Brethon, Benoit, additional, Locatelli, Franco, additional, Schrappe, Martin, additional, Scholte-van Houtem, Peggy E., additional, Valsecchi, Maria G., additional, and Pieters, Rob, additional

Published
2023
Full Text
View/download PDF

17. Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Author

Pennesi, Edoardo, primary, Brivio, Erica, additional, Ammerlaan, Anneke C.J., additional, Jiang, Yilin, additional, van der Velden, Vincent H.J., additional, Beverloo, Berna, additional, Sleight, Barbara, additional, Rives, Susana, additional, Díaz de Heredia Rubio, Cristina, additional, Bautista Sirvent, Francisco J., additional, Rubio-San-Simón, Alba, additional, Rialland, Fanny, additional, Rizzari, Carmelo, additional, Bielorai, Bella, additional, Petit, Arnaud, additional, Bruno, Bénédicte, additional, Øra, Ingrid, additional, Nilsson, Anna, additional, Engstler, Gernot, additional, Rossig, Claudia, additional, Brethon, Benoit, additional, Locatelli, Franco, additional, and Zwaan, Christian M., additional

Published
2022
Full Text
View/download PDF

18. Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Author

Pennesi, Edoardo, primary, Brivio, Erica, additional, Pelletier, Kathleen B., additional, Chen, Ying, additional, Huitema, Alwin D.R., additional, Jiang, Yilin, additional, Ammerlaan, Anneke C.J., additional, Sleight, Barbara, additional, Locatelli, Franco, additional, Van Der Sluis, Inge M., additional, Rossig, Claudia, additional, Chen-Santel, Christiane, additional, Bielorai, Bella, additional, Petit, Arnaud, additional, Stary, Jan, additional, Sramkova, Lucie, additional, Díaz de Heredia Rubio, Cristina, additional, Rives, Susana, additional, O'Marcaigh, Aengus, additional, Rizzari, Carmelo, additional, Engstler, Gernot, additional, Nysom, Karsten, additional, Rubio-San-Simón, Alba, additional, Bautista Sirvent, Francisco J., additional, Bruno, Bénédicte, additional, Bertrand, Yives, additional, Brethon, Benoit, additional, Rialland, Fanny, additional, Plat, Genevieve, additional, Dirksen, Uta, additional, Garrett, May, additional, and Zwaan, Christian M., additional

Published
2022
Full Text
View/download PDF

19. Recommandations: Infections fongiques invasives chez l’enfant immunodéprimé en hématologie pédiatrique : recommandations de prise en charge au sein des centres de la SFCE

Author

Alby-Laurent, Fanny, Chahla, Wadi Abou, Brethon, Benoit, Dupont, Damien, Gandemer, Virginie, Gueguen, Gwénaelle, Lanternier, Fanny, Pasquet, Marlène, Philippe, Michaël, Pluchart, Claire, Domenech, Carine, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Lille, Hôpital Robert Debré, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut Gustave Roussy (IGR), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Léon Bérard [Lyon], Centre Hospitalier Universitaire de Reims (CHU Reims), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, and Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe)

Subjects
[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Prophylaxis, Leucémie de l’enfant, [SDV]Life Sciences [q-bio], Childhood leukaemia, Treatment, Infection fongique invasive, Invasive fungal infection, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Diagnosis, Prophylaxie, Diagnostic, Traitement, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology
Abstract

National audience; INTRODUCTION: To date, invasive fungal infections (IFIs) are still responsible for a high mortality rate in children managed for haematological malignancy. Although Candida and Aspergillus infections remain in the majority, emerging fungal infections are increasingly common. Children differ from adults in their pathology and treatment, as well as in their prior fungal colonisation and unique pharmacokinetics. Therefore, we propose here specific paediatric management recommendations for IFIs in haematology. METHODS: We based our recommendations on a review of the literature, including the latest ECIL recommendations, an analysis of practices and a collection of expert opinions. RESULTS AND DISCUSSION: In France, approximately 5% of children treated for haematological malignancy or who have received a bone marrow allograft present an IFI. These IFIs are equally divided between yeast infections (mainly due to Candida albicans) and filamentous infections (mainly aspergillosis) and 16% are IFIs due to emerging fungi, half of which are due to Mucorales. In these recommendations, we recall the diagnostic criteria for proven or probable IFI according to the Donnelly classification, then we propose strategies for screening, diagnosing, evaluating the extension and treating these three types of IFI. We also detail the diagnostic and therapeutic management of chronic disseminated candidiasis. We also discuss prophylactic measures, including environmental measures which are of primary importance in children.; IntroductionLes infections fongiques invasives (IFI) sont encore responsables d’un taux élevé de mortalité chez les enfants pris en charge pour une hémopathie maligne. Bien que les infections à Candida et Aspergillus demeurent majoritaires, des infections à champignons émergents sont de plus en plus fréquentes. Les enfants diffèrent des adultes, tant par leur pathologie et leur traitement, que par leur colonisation fongique préalable et une pharmacocinétique qui leur est propre. Aussi, nous proposons ici des recommandations de prise en charge pédiatriques spécifiques des IFI en hématologie.MéthodesNous nous sommes appuyés sur une analyse de la littérature incluant les dernières recommandations de l’ECIL (European Conference on Infections in Leukaemia), sur une analyse des pratiques et un recueil d’avis d’experts.Résultats et discussionEn France, environ 5 % des enfants traités pour une hémopathie maligne ou ayant bénéficié d’une allogreffe de cellules souches hématopoïétiques présentent une IFI. Ces IFI sont réparties, de façon égale, entre infections à levures (majoritairement dues à Candida albicans) et filamenteux (aspergilloses principalement) et 16 % sont des IFI à champignons émergents, dont la moitié à Mucorales. Dans ces recommandations, nous rappelons les critères diagnostiques d’IFI prouvée ou probable selon la classification de Donnelly ; puis, nous proposons des stratégies pour dépister, diagnostiquer, évaluer l’extension et traiter ces trois types d’IFI. Nous détaillons aussi la prise en charge diagnostique et thérapeutique des candidoses disséminées chroniques. Nous évoquons également les mesures prophylactiques, incluant les mesures environnementales qui sont au premier plan chez l’enfant.

Published
2022

20. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies

Author

Bergeron, Anne, Porcher, Raphaël, Sulahian, Annie, de Bazelaire, Cédric, Chagnon, Karine, Raffoux, Emmanuel, Vekhoff, Anne, Cornet, Muriel, Isnard, Françoise, Brethon, Benoit, Lacroix, Claire, Poirot, Jean Louis, Bouges, Claire, Derouin, Francis, Tazi, Abdellatif, and Ribaud, Patricia

Published
2012
Full Text
View/download PDF

22. A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

Author

Van Der Sluis, Inge M., primary, De Lorenzo, Paola, additional, Kotecha, Rishi Sury, additional, Attarbaschi, Andishe, additional, Escherich, Gabriele, additional, Nysom, Karsten, additional, Stary, Jan, additional, Ferster, Alina, additional, Brethon, Benoit, additional, Ancliff, Phillip, additional, Biondi, Andrea, additional, Valsecchi, Maria Grazia, additional, and Pieters, Rob, additional

Published
2021
Full Text
View/download PDF

23. Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Author

Stutterheim, Janine, primary, De Lorenzo, Paola, additional, Van Der Sluis, Inge M., additional, Alten, Julia, additional, Ancliffe, Philip, additional, Attarbaschi, Andishe, additional, Aversa, Luis Alberto, additional, Boer, Judith M., additional, Biondi, Andrea, additional, Brethon, Benoit, additional, Diaz, Paulina, additional, Gazzaniga, Giovanni, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Kotecha, Rishi S, additional, Lausen, Birgitte, additional, Leung, Alex WK, additional, Locatelli, Franco, additional, Silverman, Lewis B., additional, Stary, Jan, additional, Szczepanski, Tomasz, additional, Van Der Velden, Vincent H.J., additional, Vora, Ajay, additional, Zuna, Jan, additional, Schrappe, Martin, additional, Grazia Valsecchi, Maria, additional, and Pieters, Rob, additional

Published
2021
Full Text
View/download PDF

25. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Author

Mukkada, Sheena, primary, Bhakta, Nickhill, additional, Chantada, Guillermo L, additional, Chen, Yichen, additional, Vedaraju, Yuvanesh, additional, Faughnan, Lane, additional, Homsi, Maysam R, additional, Muniz-Talavera, Hilmarie, additional, Ranadive, Radhikesh, additional, Metzger, Monika, additional, Friedrich, Paola, additional, Agulnik, Asya, additional, Jeha, Sima, additional, Lam, Catherine, additional, Dalvi, Rashmi, additional, Hessissen, Laila, additional, Moreira, Daniel C, additional, Santana, Victor M, additional, Sullivan, Michael, additional, Bouffet, Eric, additional, Caniza, Miguela A, additional, Devidas, Meenakshi, additional, Pritchard-Jones, Kathy, additional, Rodriguez-Galindo, Carlos, additional, Ribelles, A Juan, additional, Balduzzi, Adriana, additional, Elhaddad, Alaa, additional, Casanovas, Alejandra, additional, Garcia Velazquez, Alejandra, additional, Laptsevich, Aliaksandra, additional, Chang, Alicia, additional, F. Sampaio, Alessandra Lamenha, additional, González Prieto, Almudena, additional, Lassaletta, Alvaro, additional, Suarez M, Amaranto, additional, Alcasabas, Ana Patricia, additional, Colita, Anca, additional, Morales La Madrid, Andres, additional, Samudio, Angélica, additional, Tondo, Annalisa, additional, Colombini, Antonella, additional, Kattamis, Antonis, additional, Lopez Facundo, N Araceli, additional, Bhattacharyya, Arpita, additional, Alimi, Aurélia, additional, Phulpin, Aurélie, additional, Vakrmanova, Barbora, additional, Aksoy, Basak A, additional, Brethon, Benoit, additional, Kobuin, Jator Brian, additional, Nolasco Monteiro, Carla, additional, Paillard, Catherine, additional, Vezina, Catherine, additional, Ceyhun, Bozkurt, additional, Hentea, Cristiana, additional, Meazza, Cristina, additional, Ortiz-Morales, Daniel, additional, Solorzano, Roque Daniel, additional, Arce Cabrera, Daniela, additional, Zama, Daniele, additional, Ghosh, Debjani, additional, Ramírez-Rivera, Diana, additional, Calle Jara, Doris A, additional, Janic, Dragana, additional, Rey Helo, Elianneth, additional, Gouache, Elodie, additional, Guerrero Quiroz, Enmanuel, additional, Lopez, Enrique, additional, Thebault, Eric, additional, Maradiegue, Essy, additional, de Berranger, Eva, additional, Ebeid, Fatma S E, additional, Galaverna, Federica, additional, Antillon-Klussmann, Federico, additional, Espinoza Chacur, Felipe, additional, Negro, Fernando Daniel, additional, Carraro, Francesca, additional, Compagno, Francesca, additional, Barriga, Francisco, additional, Tamayo Pedraza, Gabriela, additional, Sanchez Fernandez, Gissela, additional, Naidu, Gita, additional, Tokuc, Gülnur, additional, Alias, Hamidah, additional, B Segocio, Hannah Grace, additional, Boudiaf, Houda, additional, Asetre Luna, Imelda, additional, Maia, Iris, additional, Astigarraga, Itziar, additional, Maza, Ivan, additional, Montoya Vásquez, Jacqueline E, additional, Jazbec, Janez, additional, Lazic, Jelena, additional, Beck Dean, Jeniffer, additional, Rouger-Gaudichon, Jeremie, additional, Contreras González, Johanny Carolina, additional, Huerta Aragonés, Jorge, additional, Fuster, José L, additional, Quintana, Juan, additional, Palma, Julia, additional, Svojgr, Karel, additional, Quintero, Karina, additional, Malic Tudor, Karolina, additional, Georgantzi, Kleopatra, additional, P Schultz, Kris Ann, additional, Ureña Horno, Laura, additional, Fraquelli, Lidia, additional, Meneghello, Linda, additional, Shalaby, Lobna, additional, Macias Mora, Lola L, additional, A Renner, Lorna, additional, Nunes Silva, Luciana, additional, Sisinni, Luisa, additional, Hammad, Mahmoud, additional, Fernández Sanmartín, M, additional, Zubieta A, C Marcela, additional, Drozdowski, María Constanza, additional, Kourti, Maria, additional, Palladino, Marcela María, additional, Miranda Madrazo, Maria R, additional, Poiree, Marilyne, additional, Popova, Marina, additional, Melgar, Mario, additional, Baragaño, Marta, additional, Avilés-Robles, Martha J, additional, Provenzi, Massimo, additional, Mendes Lins, Mecneide, additional, Fatih Orhan, Mehmet, additional, Villarroel, Milena, additional, Jerónimo, Mónica, additional, Varas Palma, Mónica, additional, Rafie Raza, Muhammad, additional, M Justin, Mulindwa, additional, Shaheen, Najma, additional, Domínguez-Pinilla, Nerea, additional, Whipple, Nicholas S, additional, André, Nicolas, additional, Hrusak, Ondrej, additional, Velasco Puyó, Pablo, additional, Zacasa Vargas, Pamela, additional, Olate Mellado, Paola, additional, Yola Gassant, Pascale, additional, Diaz Romero, Paulina, additional, De Santis, Raffaella, additional, Kebudi, Rejin, additional, Boranbayeva, Riza, additional, Vasquez, Roberto, additional, Segura, Romel A., additional, Rosado, Roy Enrique, additional, Gómez, Sandra, additional, Raimbault, Sandra, additional, Gunasekera, Sanjeeva, additional, Makkeyah, Sara M, additional, Buyukkapu Bay, Sema, additional, M Gómez, Sergio, additional, Bouttefroy, Séverine, additional, Islam, Shahnoor, additional, Abouelnaga, Sherif, additional, Torres, Silvio Fabio, additional, Cesaro, Simone, additional, Nunes, Sofia, additional, Rouxinol, Soraia, additional, Bhaumik, Sucharita, additional, Saliyeva, Symbat, additional, Inostroza, Tamara, additional, Velasquez, Thelma, additional, Hnin, Tint Myo, additional, Norén-Nyström, Ulrika, additional, Baretta, Valentina, additional, Jimenez-Antolinez, Yajaira Valentine, additional, Pérez Alonso, Vanesa, additional, Ayer Miller, Vanessa, additional, Gandemer, Virginie, additional, Lotero, Viviana, additional, Mishkova, Volha, additional, Gómez-García, Wendy, additional, Margaryan, Yeva, additional, and Syed, Yumna, additional

Published
2021
Full Text
View/download PDF

27. Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Author

Stutterheim, J, van der Sluis, I, de Lorenzo, P, Alten, J, Ancliffe, P, Attarbaschi, A, Brethon, B, Biondi, A, Campbell, M, Cazzaniga, G, Escherich, G, Ferster, A, Kotecha, R, Lausen, B, Li, C, Lo Nigro, L, Locatelli, F, Marschalek, R, Meyer, C, Schrappe, M, Stary, J, Vora, A, Zuna, J, van der Velden, V, Szczepanski, T, Valsecchi, M, Pieters, R, Stutterheim, Janine, van der Sluis, Inge M, de Lorenzo, Paola, Alten, Julia, Ancliffe, Philip, Attarbaschi, Andishe, Brethon, Benoit, Biondi, Andrea, Campbell, Myriam, Cazzaniga, Giovanni, Escherich, Gabriele, Ferster, Alina, Kotecha, Rishi S, Lausen, Birgitte, Li, Chi Kong, Lo Nigro, Luca, Locatelli, Franco, Marschalek, Rolf, Meyer, Claus, Schrappe, Martin, Stary, Jan, Vora, Ajay, Zuna, Jan, van der Velden, Vincent H J, Szczepanski, Tomasz, Valsecchi, Maria Grazia, Pieters, Rob, Stutterheim, J, van der Sluis, I, de Lorenzo, P, Alten, J, Ancliffe, P, Attarbaschi, A, Brethon, B, Biondi, A, Campbell, M, Cazzaniga, G, Escherich, G, Ferster, A, Kotecha, R, Lausen, B, Li, C, Lo Nigro, L, Locatelli, F, Marschalek, R, Meyer, C, Schrappe, M, Stary, J, Vora, A, Zuna, J, van der Velden, V, Szczepanski, T, Valsecchi, M, Pieters, R, Stutterheim, Janine, van der Sluis, Inge M, de Lorenzo, Paola, Alten, Julia, Ancliffe, Philip, Attarbaschi, Andishe, Brethon, Benoit, Biondi, Andrea, Campbell, Myriam, Cazzaniga, Giovanni, Escherich, Gabriele, Ferster, Alina, Kotecha, Rishi S, Lausen, Birgitte, Li, Chi Kong, Lo Nigro, Luca, Locatelli, Franco, Marschalek, Rolf, Meyer, Claus, Schrappe, Martin, Stary, Jan, Vora, Ajay, Zuna, Jan, van der Velden, Vincent H J, Szczepanski, Tomasz, Valsecchi, Maria Grazia, and Pieters, Rob

Abstract

Purpose: Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value of minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within the Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style consolidation (araC, daunorubicin, etoposide/mitoxantrone, araC, etoposide). Materials and methods: MRD was measured in 249 infants by DNA-based polymerase chain reaction of rearranged KMT2A, immunoglobulin, and/or T-cell receptor genes, at the end of induction (EOI) and end of consolidation (EOC). MRD results were classified as negative, intermediate (< 5 × 10-4), and high (≥ 5 × 10-4). Results: EOI MRD levels predicted outcome with 6-year disease-free survival (DFS) of 60.2% (95% CI, 43.2 to 73.6), 45.0% (95% CI, 28.3 to 53.1), and 33.8% (95% CI, 23.8 to 44.1) for infants with negative, intermediate, and high EOI MRD levels, respectively (P = .0039). EOC MRD levels were also predictive of outcome, with 6-year DFS of 68.2% (95% CI, 55.2 to 78.1), 40.1% (95% CI, 28.1 to 51.9), and 11.9% (95% CI, 2.6 to 29.1) for infants with negative, intermediate, and high EOC MRD levels, respectively (P < .0001). Analysis of EOI MRD according to the type of consolidation treatment showed that infants treated with lymphoid-style consolidation had 6-year DFS of 78.2% (95% CI, 51.4 to 91.3), 47.2% (95% CI, 33.0 to 60.1), and 23.2% (95% CI, 12.1 to 36.4) for negative, intermediate, and high MRD levels, respectively (P < .0001), while for myeloid-style-treated patients the corresponding figures were 45.0% (95% CI, 23.9 to 64.1), 41.3% (95% CI, 23.2 to 58.5), and 45.9% (95% CI, 29.4 to 60.9). Conclusion: This study provides support for the idea that induction therapy selects patients for subsequent therapy; infants with high EOI MRD may benefit from AML-like consolidation (DFS 45.9% v 23.2%), whereas patients with low EOI MRD may bene

Published
2021

28. Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Author

Stutterheim, Janine, van der Sluis, Inge M., de Lorenzo, Paola, Alten, Julia, Ancliffe, Philip, Attarbaschi, Andishe, Brethon, Benoit, Biondi, Andrea, Campbell, Myriam, Cazzaniga, Giovanni, Escherich, Gabriele, Ferster, Alina, Kotecha, Rishi S., Lausen, Birgitte, Li, Chi Kong, Lo Nigro, Luca, Locatelli, Franco, Marschalek, Rolf, Meyer, Claus, Schrappe, Martin, Stary, Jan, Vora, Ajay, Zuna, Jan, van der Velden, Vincent H.J., Szczepanski, Tomasz, Valsecchi, Maria Grazia, Pieters, Rob, Stutterheim, Janine, van der Sluis, Inge M., de Lorenzo, Paola, Alten, Julia, Ancliffe, Philip, Attarbaschi, Andishe, Brethon, Benoit, Biondi, Andrea, Campbell, Myriam, Cazzaniga, Giovanni, Escherich, Gabriele, Ferster, Alina, Kotecha, Rishi S., Lausen, Birgitte, Li, Chi Kong, Lo Nigro, Luca, Locatelli, Franco, Marschalek, Rolf, Meyer, Claus, Schrappe, Martin, Stary, Jan, Vora, Ajay, Zuna, Jan, van der Velden, Vincent H.J., Szczepanski, Tomasz, Valsecchi, Maria Grazia, and Pieters, Rob

Abstract

PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value of minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within the Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style consolidation (araC, daunorubicin, etoposide/mitoxantrone, araC, etoposide). MATERIALS AND METHODS: MRD was measured in 249 infants by DNA-based polymerase chain reaction of rearranged KMT2A, immunoglobulin, and/or T-cell receptor genes, at the end of induction (EOI) and end of consolidation (EOC). MRD results were classified as negative, intermediate (< 5 × 10-4), and high (≥ 5 × 10-4). RESULTS: EOI MRD levels predicted outcome with 6-year disease-free survival (DFS) of 60.2% (95% CI, 43.2 to 73.6), 45.0% (95% CI, 28.3 to 53.1), and 33.8% (95% CI, 23.8 to 44.1) for infants with negative, intermediate, and high EOI MRD levels, respectively (P = .0039). EOC MRD levels were also predictive of outcome, with 6-year DFS of 68.2% (95% CI, 55.2 to 78.1), 40.1% (95% CI, 28.1 to 51.9), and 11.9% (95% CI, 2.6 to 29.1) for infants with negative, intermediate, and high EOC MRD levels, respectively (P < .0001). Analysis of EOI MRD according to the type of consolidation treatment showed that infants treated with lymphoid-style consolidation had 6-year DFS of 78.2% (95% CI, 51.4 to 91.3), 47.2% (95% CI, 33.0 to 60.1), and 23.2% (95% CI, 12.1 to 36.4) for negative, intermediate, and high MRD levels, respectively (P < .0001), while for myeloid-style-treated patients the corresponding figures were 45.0% (95% CI, 23.9 to 64.1), 41.3% (95% CI, 23.2 to 58.5), and 45.9% (95% CI, 29.4 to 60.9). CONCLUSION: This study provides support for the idea that induction therapy selects patients for subsequent therapy; infants with high EOI MRD may benefit from AML-like consolidation (DFS 45.9% v 23.2%), whereas patients with low EOI MRD may b

Published
2021

29. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Author

Porkka, Kimmo, Koskenvesa, Perttu, Lundán, Tuija, Rimpiläinen, Johanna, Mustjoki, Satu, Smykla, Richard, Wild, Robert, Luo, Roger, Arnan, Montserrat, Brethon, Benoit, Eccersley, Lydia, Hjorth-Hansen, Henrik, Höglund, Martin, Klamova, Hana, Knutsen, Håvar, Parikh, Suhag, Raffoux, Emmanuel, Gruber, Franz, Brito-Babapulle, Finella, Dombret, Hervé, Duarte, Rafael F., Elonen, Erkki, Paquette, Ron, Zwaan, C.Michel, and Lee, Francis Y.F.

Published
2008
Full Text
View/download PDF

30. Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Author

Stutterheim, Janine, primary, van der Sluis, Inge M., additional, de Lorenzo, Paola, additional, Alten, Julia, additional, Ancliffe, Philip, additional, Attarbaschi, Andishe, additional, Brethon, Benoit, additional, Biondi, Andrea, additional, Campbell, Myriam, additional, Cazzaniga, Giovanni, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Kotecha, Rishi S., additional, Lausen, Birgitte, additional, Li, Chi Kong, additional, Lo Nigro, Luca, additional, Locatelli, Franco, additional, Marschalek, Rolf, additional, Meyer, Claus, additional, Schrappe, Martin, additional, Stary, Jan, additional, Vora, Ajay, additional, Zuna, Jan, additional, van der Velden, Vincent H. J., additional, Szczepanski, Tomasz, additional, Valsecchi, Maria Grazia, additional, and Pieters, Rob, additional

Published
2021
Full Text
View/download PDF

31. Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Author

Stutterheim, Janine, primary, van der Sluis, Inge M., additional, De Lorenzo, Paola, additional, Alten, Julia, additional, Ancliff, Philip, additional, Attarbaschi, Andishe, additional, Brethon, Benoit, additional, Biondi, Andrea, additional, Campbell, Myriam, additional, Cazzaniga, Giovanni, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Kotecha, Rishi Sury, additional, Lausen, Birgitte, additional, Li, Chi Kong, additional, Lo Nigro, Luca, additional, Locatelli, Franco, additional, Marschalek, Rolf, additional, Schrappe, Martin, additional, Stary, Jan, additional, Vora, Ajay, additional, Zuna, Jan, additional, Van Der Velden, Vincent H.J., additional, Szczepanski, Tomasz, additional, Grazia Valsecchi, Maria, additional, and Pieters, Rob, additional

Published
2020
Full Text
View/download PDF

32. Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Author

Locatelli, Franco, primary, Zugmaier, Gerhard, additional, Mergen, Noemi, additional, Bader, Peter, additional, Jeha, Sima, additional, Schlegel, Paul-Gerhardt, additional, Bourquin, Jean-Pierre, additional, Handgretinger, Rupert, additional, Brethon, Benoit, additional, Rössig, Claudia, additional, Kormany, William, additional, Viswagnachar, Puneeth, additional, and Chen-Santel, Christiane, additional

Published
2020
Full Text
View/download PDF

33. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22 ‐positive B‐cell acute lymphoblastic leukaemia

Author

Calvo, Charlotte, primary, Cabannes‐Hamy, Aurélie, additional, Adjaoud, Dalila, additional, Bruno, Bénédicte, additional, Blanc, Laurence, additional, Boissel, Nicolas, additional, Tabone, Marie‐Dominique, additional, Willson‐Plat, Geneviève, additional, Villemonteix, Juliette, additional, Baruchel, André, additional, and Brethon, Benoit, additional

Published
2020
Full Text
View/download PDF

35. Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Author

Locatelli, Franco, primary, Zugmaier, Gerhard, additional, Bader, Peter, additional, Jeha, Sima, additional, Schlegel, Paul-Gerhardt, additional, Bourquin, Jean-Pierre, additional, Handgretinger, Rupert, additional, Brethon, Benoit, additional, Rossig, Claudia, additional, and Chen-Santel, Christiane, additional

Published
2019
Full Text
View/download PDF

36. A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Author

Brivio, Erica, primary, Lopez-Yurda, Marta, additional, Ownes, Cormac, additional, Díaz de Heredia, Cristina, additional, Bielorai, Bella, additional, Rossig, Claudia, additional, van der Velden, Vincent, additional, Ammerlaan, Anneke C.J., additional, van der Sluis, Inge M., additional, Den Boer, Monique L., additional, Chen, Ying, additional, Sleight, Barbara, additional, Brethon, Benoit, additional, Nysom, Karsten, additional, Stary, Jan, additional, Øra, Ingrid, additional, Chen-Santel, Christiane, additional, Vinti, Luciana, additional, Locatelli, Franco, additional, and Zwaan, Christian Michel, additional

Published
2019
Full Text
View/download PDF

39. End-of-life care in children and adolescents with cancer: perspectives from a French pediatric oncology care network

Author

Blais, Sophie, Cohen-Gogo, Sarah, Gouache, Elodie, Guerrini-Rousseau, Lea, Brethon, Benoit, Rahal, Ilhem, Petit, Arnaud, Raimondo, Graziella, Pellegrino, Beatrice, and Orbach, Daniel

Abstract

Background: In developed countries, cancer remains the leading cause of pediatric death from illness after the neonatal period.Objective: To describe the end-of-life care characteristics of children and adolescents with solid tumors (ST) or hematologic malignancies (HM) who died from tumor progression in the Île-de-France area.Methods: This is a regional, multicentric, retrospective review of medical files of all children and adolescents with cancer who died over a 1-year period. Extensive data from the last 3 months of life were collected.Results: A total of 99 eligible patients died at a median age of 9.8 years (range, 0.3–24 years). The most frequent terminal symptoms were pain (n = 86), fatigue (n = 84), dyspnea (n = 49), and anorexia (n = 41). Median number of medications per patient was 8 (range, 3–18). Patients required administration of opioids (n = 91), oxygen (n = 36), and/or sedation (n = 61). Decision for palliative care was present in all medical records and do-not-resuscitate orders in 90/99 cases. Symptom prevalence was comparable between children and adolescents with ST and HM. A wish regarding the place of death had been expressed for 64 patients and could be respected in 42 cases. Death occurred in hospital for 75 patients.Conclusions: This study represents a large and informative cohort illustrating current pediatric palliative care approaches in pediatric oncology. End-of-life remains an active period of care requiring coordination of multiple care teams.

Published
2022
Full Text
View/download PDF

40. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin

Author

Alanio, Alexandra, Brethon, Benoit, Feuilhade De Chauvin, Martine, de Kerviler, Eric, Leblanc, Thierry, Lacroix, Claire, Baruchel, Andre, and Menotti, Jean

Subjects
Caspofungin -- Dosage and administration, Lung diseases, Fungal -- Care and treatment, Neutropenia -- Care and treatment, Health, Health care industry
Published
2008

41. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study

Author

Pieters, Rob, primary, De Lorenzo, Paola, additional, Ancliffe, Philip, additional, Aversa, Luis Alberto, additional, Brethon, Benoit, additional, Biondi, Andrea, additional, Campbell, Myriam, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Gardner, Rebecca A, additional, Kotecha, Rishi Sury, additional, Lausen, Birgitte, additional, Li, Chi Kong, additional, Locatelli, Franco, additional, Attarbaschi, Andishe, additional, Peters, Christina, additional, Rubnitz, Jeffrey E., additional, Silverman, Lewis B., additional, Stary, Jan, additional, Szczepanski, Tomasz, additional, Vora, Ajay, additional, Schrappe, Martin, additional, and Valsecchi, Maria Grazia, additional

Published
2019
Full Text
View/download PDF

42. High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Author

Locatelli, Franco, primary, Zugmaier, Gerhard, additional, Bader, Peter, additional, Jeha, Sima, additional, Schlegel, Paul-Gerhardt, additional, Bourquin, Jean-Pierre, additional, Handgretinger, Rupert, additional, Brethon, Benoit, additional, Rossig, Claudia, additional, and Chen-Santel, Christiane, additional

Published
2018
Full Text
View/download PDF

44. Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Author

Pieters, Rob, primary, De Lorenzo, Paola, additional, Ancliffe, Philip, additional, Aversa, Luis Alberto, additional, Brethon, Benoit, additional, Biondi, Andrea, additional, Campbell, Myriam, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Gardner, Rebecca, additional, Kotecha, Rishi Sury, additional, Lausen, Birgitte, additional, Li, Chi Kong, additional, Locatelli, Franco, additional, Attarbaschi, Andishe, additional, Peters, Christina, additional, Rubnitz, Jeffrey, additional, Silverman, Lewis B., additional, Stary, Jan, additional, Szczepanski, Tomasz, additional, Vora, Ajay, additional, Schrappe, Martin, additional, and Valsecchi, Maria Grazia, additional

Published
2018
Full Text
View/download PDF

45. Clinical Implications of Minimal Residual Disease Detection in Infants With -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.

Author

Stutterheim, Janine, van der Sluis, Inge M, de Lorenzo, Paola, Alten, Julia, Ancliffe, Philip, Attarbaschi, Andishe, Brethon, Benoit, Biondi, Andrea, Campbell, Myriam, Cazzaniga, Giovanni, Escherich, Gabriele, Ferster, Alina, Kotecha, Rishi S, Lausen, Birgitte, Li, Chi Kong, Lo Nigro, Luca, Locatelli, Franco, Marschalek, Rolf, Meyer, Claus, and Schrappe, Martin

Published
2021
Full Text
View/download PDF

46. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia

Author

Bertrand Yves, Leblanc Thierry, Yakouben Karima, Galambrun Claire, Auvrignon Anne, Brethon Benoit, Leverger Guy, and Baruchel André

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ AML. We conducted a retrospective multicenter study of 12 children treated with GO on a compassionate basis (median age 5.5 y). Three patients (2 MDS/AML, 1 JMML) were refractory to first-line treatment, 8 patients with de novo AML were in refractory first relapse, and one patient with de novo AML was in 2nd relapse after stem cell transplantation (SCT). CD33 expression exceeded 20% in all cases. Methods GO was administered alone, at a unit dose of 3–9 mg/m2, once (3 patients), twice (3 patients), three (5 patients) or five times (1 patient). Mean follow-up was 128 days (8–585 d). Results There were three complete responses (25%) leading to further curative treatment (SCT). Treatment failed in the other nine patients, and only one patient was alive at the end of follow-up. NCI-CTC grade III/IV adverse events comprised hematological toxicity (n = 12), hypertransaminasemia (n = 2), allergy and hyperbilirubinemia (1 case each). There was only one major adverse event (grade IV allergy). No case of sinusoidal obstruction syndrome occurred. Conclusion These results warrant a prospective trial of GO in a larger population of children with AML.

Published
2006
Full Text
View/download PDF

47. Tolerance to arsenic trioxide combined with all‐trans‐retinoic acid in children with acute promyelocytic leukaemia in France.

Author

Garcia Spezza, Emmanuel, Brethon, Benoit, Petit, Arnaud, Mazingue, Franҫoise, Gandemer, Virginie, Boissel, Nicolas, Carausu, Liana, Reguerre, Yves, Leverger, Guy, and Ducassou, Stephane

Subjects
*ACUTE promyelocytic leukemia, *ARSENIC trioxide, *LEUKEMIA
Abstract

Differentiation syndrome is a potentially life-threatening complication developing in 2-5-30% of patients with newly diagnosed APL receiving ATRA. Nine patients (42-9%) underwent differentiation syndrome prophylaxis (dexamethasone), and four (19%) developed true differentiation syndrome. All patients achieved cytological remission during induction therapy with a median of 34 [28;60] days and molecular remission with a median of 8 [4-26] weeks. Combined ATRA/ATO therapy for paediatric patients with SR APL was well tolerated without any severe short-term toxicity. [Extracted from the article]

Published
2020
Full Text
View/download PDF

48. A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia

Author

Zwaan, C. Michel, primary, Söderhäll, Stefan, additional, Brethon, Benoit, additional, Luciani, Matteo, additional, Rizzari, Carmelo, additional, Stam, Ronald W., additional, Besse, Emmanuelle, additional, Dutreix, Catherine, additional, Fagioli, Franca, additional, Ho, Phoenix A., additional, Dufour, Carlo, additional, and Pieters, Rob, additional

Published
2018
Full Text
View/download PDF

49. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study

Author

van Eijkelenburg, Natasha K.A., primary, Rasche, Mareike, additional, Ghazaly, Essam, additional, Dworzak, Michael N., additional, Klingebiel, Thomas, additional, Rossig, Claudia, additional, Leverger, Guy, additional, Stary, Jan, additional, De Bont, Eveline S.J.M., additional, Chitu, Dana A., additional, Bertrand, Yves, additional, Brethon, Benoit, additional, Strahm, Brigitte, additional, van der Sluis, Inge M., additional, Kaspers, Gertjan J.L., additional, Reinhardt, Dirk, additional, and Zwaan, C. Michel, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results